ALPHAMAB ONCOLO.DL-000002 - Asset Resilience Ratio
ALPHAMAB ONCOLO.DL-000002 (3NK) has an Asset Resilience Ratio of 34.73% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does ALPHAMAB ONCOLO.DL-000002 carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how ALPHAMAB ONCOLO.DL-000002's Asset Resilience Ratio has changed over time. See 3NK total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ALPHAMAB ONCOLO.DL-000002's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 3NK stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €819.23 Million | 34.73% |
| Total Liquid Assets | €819.23 Million | 34.73% |
Asset Resilience Insights
- Very High Liquidity: ALPHAMAB ONCOLO.DL-000002 maintains exceptional liquid asset reserves at 34.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ALPHAMAB ONCOLO.DL-000002 Industry Peers by Asset Resilience Ratio
Compare ALPHAMAB ONCOLO.DL-000002's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for ALPHAMAB ONCOLO.DL-000002 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for ALPHAMAB ONCOLO.DL-000002.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.49% | €459.35 Million ≈ $537.02 Million |
€2.24 Billion ≈ $2.62 Billion |
+5.46pp |
| 2023-12-31 | 15.03% | €321.25 Million ≈ $375.57 Million |
€2.14 Billion ≈ $2.50 Billion |
+1.75pp |
| 2022-12-31 | 13.28% | €281.19 Million ≈ $328.74 Million |
€2.12 Billion ≈ $2.48 Billion |
-30.42pp |
| 2021-12-31 | 43.70% | €1.18 Billion ≈ $1.38 Billion |
€2.71 Billion ≈ $3.16 Billion |
-- |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more